Glioblastoma, also called glioblastoma multiforme (GBM), is the most common and aggressive type of primary brain neoplasm. Gliomas in general are subdivided into astrocytomas, oligodendrogliomas, ependymomas, and mixed gliomas, based on the origin cell type. Furthermore, according to the World Health Organization (WHO), astrocytomas can be classified by grade based on factors aimed at measuring the aggressiveness of the tumor, such as mitotic activity, vascular proliferation, and necrosis. According to this classification system, GBM is defined as a grade IV astrocytoma. Due to its aggressive nature, GBM typically develops rapidly, often presenting with a clinical history ranging from three to six months. Moreover, the lack of effective treatment options for the disease leaves patients with a poor median survival of 15 months. GBM occurs primarily in the brain, often in the supratentorial region (temporal, frontal, occipital, and parietal lobes), although it can be found in other parts of the central nervous system (CNS). 

This Datamonitor Healthcare report contains a Market Spotlight module.